Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ALPS vs ABVC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ALPS Captures Overall Composite Edge (31.6 SELL vs 47.4 HOLD), While ABVC Leads 2–1 on Growth & Valuation Pillars

ALPS Overall Winner 6-Pillar Tally: ALPS 1 – 2 ABVC (3 Tie) Matrix Metrics: ALPS 3 – 3 ABVC

As of Nov 20, 2026, ALPS (ALPS) captures the overall head-to-head institutional edge over ABVC BioPharma, Inc. (ABVC) on higher Unified Composite conviction (31.6/100 SELL vs. 47.4/100 HOLD) after splitting the core matrix 3–3 (led by Balance Sheet & Cash Flow), while ABVC wins 2–1 across the 6-pillar growth and valuation breakdown. ALPS trades at $1.15 (N/M Forward P/E, 0.0% operating margin) versus ABVC at $0.87 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While ABVC currently prints a higher short-term Unified Composite Score (47.4/100 HOLD vs. ALPS 31.6/100 SELL), ALPS captures the overall institutional head-to-head verdict (3–3 matrix metrics and 1–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +104.5% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ALPS vs ABVC
ALPS US Equity Head-to-Head Winner
ALPS
Institutional Equity
$1.15
-3.36% 1D
Market Cap $37.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 6.25β · 1362% Vol
Unified Composite Score
31.6 / 100 SELL
Tech 50.0 Fund 29.0 Flow 50.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (47.8% over 20 days), RSI 67
RSI-14: 66.8 · SMA20: $0.79 · SMA50: $0.54
ABVC NASDAQ
ABVC BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$0.87
-1.56% 1D
Market Cap $23.9M
TTM Revenue $797,916
Forward P/E N/M
Beta / 30D Vol 1.24β · 44% Vol
Unified Composite Score
47.4 / 100 HOLD
Tech 43.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 35.2 · SMA20: $0.98 · SMA50: $1.01

6-Pillar Scorecard Institutional Category Breakdown (ALPS 1 – 2 ABVC)

Columns: Metric · ALPS · ABVC
1. Valuation Multiples ABVC
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 29.9x
2. Growth & Scale ABVC
Revenue Growth (YoY) +0.0% +104.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $797,916
Market Cap $37.7M $23.9M
3. Profitability & Quality Tie
Gross Margin N/A 100.0%
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) 0.0% -52.7%
4. Balance Sheet & Cash Flow ALPS
Cash Generation (TTM) N/A -$5.8M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage 0.0% ROE $0.50 Book/Sh · -52.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ALPS (3) vs ABVC (3)
Institutional Metric ALPS ABVC Criterion Row Edge
Market Capitalization
Scale
$37.7M $23.9M Larger Scale ALPS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +104.5% Higher Growth ABVC
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
0.0% -52.7% Higher ROE ALPS
52-Week Range Position
Momentum
51% ($0–$2) 7% ($1–$3) Stronger Trend ALPS
Beta / 30D Volatility
Risk Regime
6.25β · 1362% Vol 1.24β · 44% Vol Lower Realized Risk ABVC
Unified Institutional Score
Composite Signal
31.6 / 100 (SELL) 47.4 / 100 (HOLD) Higher Composite ABVC
Trailing 12M Revenue (USD)
Operating Scale
N/A $797,916 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 29.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (0.0% ROE) -$5.8M EBITDA ($0.50 Book/Sh · -52.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ALPS +268.0 pp
ALPS: +250.72% · ABVC: -17.28%
3M Horizon ALPS +261.95 pp
ALPS: +265.08% · ABVC: +3.13%
6M Horizon ALPS +94.79 pp
ALPS: +70.78% · ABVC: -24.01%
1Y Horizon ALPS +103.44 pp
ALPS: +35.29% · ABVC: -68.15%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ALPS vs ABVC. Trailing 12-month operating profitability (ALPS 0.0% vs ABVC 0.0%) and valuation multiples (ALPS N/M vs ABVC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ALPS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E0.0% · N/M
ABVC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$797,916
Gross Margin100.0%
Op. Margin0.0%
ROE / Fwd P/E-52.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ALPS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ALPS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABVC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABVC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ALPS Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with $37.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABVC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $23.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ALPS vs ABVC Key Questions & Quantitative Answers

As of Nov 20, 2026, ALPS (ALPS) captures the overall head-to-head institutional edge over ABVC BioPharma, Inc. (ABVC) on higher Unified Composite conviction (31.6/100 SELL vs. 47.4/100 HOLD) after splitting the core matrix 3–3 (led by Balance Sheet & Cash Flow), while ABVC wins 2–1 across the 6-pillar growth and valuation breakdown. ALPS trades at $1.15 (N/M Forward P/E, 0.0% operating margin) versus ABVC at $0.87 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ABVC currently prints a higher short-term Unified Composite Score (47.4/100 HOLD vs. ALPS 31.6/100 SELL), ALPS captures the overall institutional head-to-head verdict (3–3 matrix metrics and 1–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +104.5% YoY).

ABVC leads the Growth & Scale pillar: ALPS posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ABVC at +104.5% YoY revenue growth and +0.0% YoY earnings growth on $797,916 TTM revenue (100.0% gross margin, 0.0% operating margin). On trailing 12-month operating scale, ALPS generates N/A in USD-normalized revenue versus $797,916 for ABVC. In operating R&D and SG&A reinvestment, ALPS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABVC.

ABVC screens cheaper on headline valuation multiples. ALPS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABVC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ALPS (0.0% ROE) versus ABVC (-52.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ALPS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (6.25β · 1362% Vol realized risk). By comparison, ABVC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.24β · 44% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.